Medication info
LinaMax Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

LinaMax Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceuticals Co., Ltd.
Appearance
Oval-shaped extended release tablet, white to nearly white, engraved with P251 on one side
Packaging
28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle
Approval status
Active

MFDS item code 202400613 · Approved 2024.03.22 · Insurance code 663608800

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Korea Prime Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes manage blood glucose levels more effectively by supporting dietary and exercise regimens. The combination of linagliptin and metformin works to stabilize blood glucose levels, helping to alleviate symptoms of diabetes. Therefore, this medication is used to improve blood glucose control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication is primarily used for treating diabetes and aids in controlling blood glucose levels. However, it can rarely cause a dangerous condition known as lactic acidosis, hence it should not be administered to patients with severely impaired kidney function, poor liver function, or those experiencing acute infections or dehydration. Individuals allergic to any of the components in this medication, patients with type 1 diabetes, diabetic ketoacidosis, pregnant women, or those at risk of pregnancy should also avoid using this product. During treatment, hypoglycemic symptoms may appear, so it is important to regularly check blood glucose levels, especially when combined with other hypoglycemic agents or insulin. Elderly patients with diminished renal function or those taking medications that place stress on the kidneys require special caution and should undergo regular kidney function tests. This medication can be taken regardless of meals, but alcohol consumption should be avoided as it may increase the risk of lactic acidosis. Rare adverse effects such as acute pancreatitis or skin blistering similar to bullous pemphigoid may occur, so if severe abdominal pain or skin abnormalities develop, it is essential to notify a doctor immediately. For pregnant or breastfeeding patients, it is advisable to avoid using this medication, and those planning to become pregnant should consult their physician. Do not chew, crush, or break this medication; swallow it whole. The tablet shell may be excreted in feces, which is a normal occurrence. In the event of overdose, gastrointestinal disturbances or lactic acidosis may occur, so adherence to prescribed dosages is critical, and any abnormal symptoms should prompt an immediate visit to a healthcare facility. Finally, it is important to keep this medication out of reach of children and store it in a moisture-free environment.

Side effects

Severe lactic acidosis, hypoglycemia, nasopharyngitis, allergic reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemic episodes, taste disorders, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigoid-like eruptions, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer-type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, pneumonia, hypercholesterolemia, lightheadedness, drowsiness, chest discomfort, weakness, pain, nosebleeds, oropharyngeal pain, voice disorders, allergic rhinitis, exertional dyspnea, wet cough, runny nose, lung mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, male pattern baldness, hyperhidrosis, dermatitis, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fractures, hand fractures, lacerations, palpitations, dry eyes, glaucoma, cataracts, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, thyroid goiter, anemia, nausea, gastroesophageal reflux disease, gastritis, viral upper respiratory infection, upper respiratory infection, periodontitis, influenza, mediastinitis, pharyngitis, rhinitis, upper abdominal pain, stomatitis, increased serum creatinine, chest pain, facial swelling, hyperthermia, back pain, flank pain, osteoarthritis, limb pain, subdural effusion, angina pectoris, voice disorders, epistaxis, vocal cord polyp, dyslipidemia, thyroid nodule, altered mental status, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent exposure to air or moisture. The safe storage temperature is between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness and prevents degradation.

Appearance and packaging

Appearance

Oval-shaped extended release tablet, white to nearly white, engraved with P251 on one side

Package unit

28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.